Avatar Tissue Bioprinting for Drug and ATMP Testing

Our research focuses on the development of artificial human tissues designed to serve as predictive platforms for testing medical devices, drugs, and advanced therapy medicinal products (ATMPs) to be used as New Approach Methodologies NAMS . In thsi framework, we patent FibroModel able to recapituale human fibrosis. The developed model is based on primary fibroblasts derived from healthy human tissues, including skin, lung, and kidney. These cells are embedded in a high-density collagen hydrogel and bioprinted to generate three-dimensional artificial tissues. Following fabrication, the constructs are cultured under defined biochemical stimulation to induce fibrotic features, including:

• Increased secretion of collagen and fibronectin

• Formation of fibrotic nodules

• Progressive tissue stiffening, quantitatively assessed by nanoindentation

To further strengthen the pathological relevance of our platform, we are also developing a pancreatic ductal adenocarcinoma (PDAC) model, leveraging the strong mechanistic and biological connection between fibrosis and tumor progression. This model is intended for drug and ATMP efficacy screening in a disease-relevant microenvironment.

Perfusion represents a key element in achieving a higher level of biomimicry. To this end, we generate engineered artificial blood vessels that are integrated into the tissue constructs and maintained under dynamic perfusion, enabling improved nutrient transport, waste removal, and physiological relevance.